In the FLOW trial, semaglutide reduced risk of clinically important kidney outcomes and reduced cardiovascular death in people with type 2 diabetes and chronic kidney disease.

normativepending

Speaker

Dr. Amin Dadgar

Evidence Quote

“In people with type 2 diabetes and chronic kidney disease, the FLOW trial showed semaglutide reduced risk of clinically important kidney outcomes and reduced cardiovascular death.”

Source

Ozempic & Mounjaro: Same Shot. Opposite Results.— Dr. Amin Hedayat, MD
Created: 8/12/2026, 6:40:36 PM

Your notes

Loading notes...